The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
The US FDA’s decision not to grant an emergency use authorization for the antidepressant as a COVID-19 treatment highlights a lack of consensus among researchers about how to interpret clinical data on the drug.
Authors of a newly published study on the use of an antidepressant for COVID-19 claim the drug greatly reduces hospitalizations and mortality. But some experts question whether that’s really what the data show.
Some children who experience the severe inflammatory condition after COVID-19 may continue to experience milder problems such as muscle weakness or anxiety even after that period, according to a small observational study in the UK.
The issue’s guest editors resign after falling out with the publisher over the management of papers, including a rejected manuscript on ivermectin, that were submitted for a special issue on drug repurposing for COVID-19.